CA2130443A1 - Compositions pharmaceutiques et leur utilisation pour le traitement des troubles de carence en zinc - Google Patents
Compositions pharmaceutiques et leur utilisation pour le traitement des troubles de carence en zincInfo
- Publication number
- CA2130443A1 CA2130443A1 CA 2130443 CA2130443A CA2130443A1 CA 2130443 A1 CA2130443 A1 CA 2130443A1 CA 2130443 CA2130443 CA 2130443 CA 2130443 A CA2130443 A CA 2130443A CA 2130443 A1 CA2130443 A1 CA 2130443A1
- Authority
- CA
- Canada
- Prior art keywords
- zinc
- mineral
- substance
- compound
- containing compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000011701 zinc Substances 0.000 title claims abstract description 164
- 229910052725 zinc Inorganic materials 0.000 title claims abstract description 164
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title claims abstract description 159
- 230000002950 deficient Effects 0.000 title description 6
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 241001465754 Metazoa Species 0.000 claims abstract description 118
- 239000000126 substance Substances 0.000 claims abstract description 60
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 41
- 150000001875 compounds Chemical class 0.000 claims abstract description 40
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 30
- 239000011707 mineral Substances 0.000 claims abstract description 30
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 27
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 27
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 239000011669 selenium Substances 0.000 claims abstract description 26
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 26
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 25
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 22
- 239000000194 fatty acid Substances 0.000 claims abstract description 22
- 229930195729 fatty acid Natural products 0.000 claims abstract description 22
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 22
- 239000005864 Sulphur Substances 0.000 claims abstract description 20
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 18
- 239000011777 magnesium Substances 0.000 claims abstract description 18
- 239000012530 fluid Substances 0.000 claims abstract description 13
- -1 zinc inorganic compounds Chemical class 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 231100000572 poisoning Toxicity 0.000 claims abstract description 10
- 230000000607 poisoning effect Effects 0.000 claims abstract description 10
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 8
- 239000011575 calcium Substances 0.000 claims abstract description 8
- 238000005562 fading Methods 0.000 claims abstract description 8
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 8
- 239000008158 vegetable oil Substances 0.000 claims abstract description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 7
- 231100000678 Mycotoxin Toxicity 0.000 claims abstract description 7
- 239000002636 mycotoxin Substances 0.000 claims abstract description 7
- 230000001079 digestive effect Effects 0.000 claims abstract description 6
- 230000001747 exhibiting effect Effects 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 33
- 150000003752 zinc compounds Chemical class 0.000 claims description 24
- 235000019198 oils Nutrition 0.000 claims description 19
- 239000003921 oil Substances 0.000 claims description 18
- 210000004185 liver Anatomy 0.000 claims description 16
- 239000006185 dispersion Substances 0.000 claims description 8
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- 210000003205 muscle Anatomy 0.000 claims description 4
- 206010033675 panniculitis Diseases 0.000 claims description 4
- 210000004304 subcutaneous tissue Anatomy 0.000 claims description 4
- 231100001160 nonlethal Toxicity 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 230000006698 induction Effects 0.000 claims 1
- 230000001815 facial effect Effects 0.000 abstract description 19
- 235000010755 mineral Nutrition 0.000 abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 9
- 230000002045 lasting effect Effects 0.000 abstract description 6
- 230000000246 remedial effect Effects 0.000 abstract description 4
- 229930013930 alkaloid Natural products 0.000 abstract description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 abstract description 2
- 239000000262 estrogen Substances 0.000 abstract description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 206010048259 Zinc deficiency Diseases 0.000 abstract 1
- 229910010272 inorganic material Inorganic materials 0.000 abstract 1
- 150000003568 thioethers Chemical class 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 95
- 241001494479 Pecora Species 0.000 description 35
- 208000035475 disorder Diseases 0.000 description 25
- 229930188346 Sporidesmin Natural products 0.000 description 24
- QTONANGUNATZOU-UHFFFAOYSA-N sporidesmin-A Natural products N12C(=O)C(N(C3=O)C)(C)SSC23C(O)C2(O)C1N(C)C1=C(OC)C(OC)=C(Cl)C=C12 QTONANGUNATZOU-UHFFFAOYSA-N 0.000 description 24
- QTONANGUNATZOU-ICTVWZTPSA-N sporidesmin A Chemical compound S([C@](N(C1=O)C)(C)C(=O)N23)S[C@@]21[C@H](O)[C@@]1(O)[C@@H]3N(C)C2=C(OC)C(OC)=C(Cl)C=C21 QTONANGUNATZOU-ICTVWZTPSA-N 0.000 description 22
- 238000002347 injection Methods 0.000 description 19
- 239000007924 injection Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 229910001868 water Inorganic materials 0.000 description 15
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 14
- 150000002500 ions Chemical class 0.000 description 14
- 210000003734 kidney Anatomy 0.000 description 13
- 241000283903 Ovis aries Species 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000003053 toxin Substances 0.000 description 12
- 231100000765 toxin Toxicity 0.000 description 12
- 108700012359 toxins Proteins 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 229910052802 copper Inorganic materials 0.000 description 10
- 239000010949 copper Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 210000000496 pancreas Anatomy 0.000 description 9
- 231100000331 toxic Toxicity 0.000 description 9
- 230000002588 toxic effect Effects 0.000 description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 8
- 208000021017 Weight Gain Diseases 0.000 description 8
- 230000004584 weight gain Effects 0.000 description 8
- 235000019786 weight gain Nutrition 0.000 description 8
- 238000011160 research Methods 0.000 description 7
- 239000011787 zinc oxide Substances 0.000 description 7
- 235000014692 zinc oxide Nutrition 0.000 description 7
- 229960001296 zinc oxide Drugs 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 244000144972 livestock Species 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 241000282994 Cervidae Species 0.000 description 4
- 235000019486 Sunflower oil Nutrition 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000002249 digestive system Anatomy 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 239000002600 sunflower oil Substances 0.000 description 4
- PFNQVRZLDWYSCW-UHFFFAOYSA-N (fluoren-9-ylideneamino) n-naphthalen-1-ylcarbamate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1=NOC(=O)NC1=CC=CC2=CC=CC=C12 PFNQVRZLDWYSCW-UHFFFAOYSA-N 0.000 description 3
- 241000974009 Cervus canadensis Species 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
- 230000035987 intoxication Effects 0.000 description 3
- 231100000566 intoxication Toxicity 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 229910021653 sulphate ion Inorganic materials 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 150000003751 zinc Chemical class 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- MBEVSMZJMIQVBG-UHFFFAOYSA-N 2-(hydroxymethyl)guanidine Chemical compound NC(N)=NCO MBEVSMZJMIQVBG-UHFFFAOYSA-N 0.000 description 2
- 241000331231 Amorphocerini gen. n. 1 DAD-2008 Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000208818 Helianthus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000005083 Zinc sulfide Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002730 additional effect Effects 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009313 farming Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- GYHFUZHODSMOHU-UHFFFAOYSA-N nonanal Chemical compound CCCCCCCCC=O GYHFUZHODSMOHU-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- BHHYHSUAOQUXJK-UHFFFAOYSA-L zinc fluoride Chemical compound F[Zn]F BHHYHSUAOQUXJK-UHFFFAOYSA-L 0.000 description 2
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 description 2
- DRDVZXDWVBGGMH-UHFFFAOYSA-N zinc;sulfide Chemical compound [S-2].[Zn+2] DRDVZXDWVBGGMH-UHFFFAOYSA-N 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000283014 Dama Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 206010061291 Mineral deficiency Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 241001574249 Pithomyces chartarum Species 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- 239000004110 Zinc silicate Substances 0.000 description 1
- AMHCIOVVVSCUJB-UHFFFAOYSA-N [Se].[Cu].[Ca].[Zn] Chemical compound [Se].[Cu].[Ca].[Zn] AMHCIOVVVSCUJB-UHFFFAOYSA-N 0.000 description 1
- MAAFZJKFYPHQCO-UHFFFAOYSA-N [Se].[Cu].[Zn].[Se].[Cu].[Zn] Chemical compound [Se].[Cu].[Zn].[Se].[Cu].[Zn] MAAFZJKFYPHQCO-UHFFFAOYSA-N 0.000 description 1
- 238000010669 acid-base reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000004645 aluminates Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940038879 chelated zinc Drugs 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000002635 electroconvulsive therapy Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- MFGZXPGKKJMZIY-UHFFFAOYSA-N ethyl 5-amino-1-(4-sulfamoylphenyl)pyrazole-4-carboxylate Chemical compound NC1=C(C(=O)OCC)C=NN1C1=CC=C(S(N)(=O)=O)C=C1 MFGZXPGKKJMZIY-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000007380 fibre production Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000010758 granulomatous inflammation Diseases 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940025708 injectable product Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012260 resinous material Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 229940065287 selenium compound Drugs 0.000 description 1
- 150000003343 selenium compounds Chemical class 0.000 description 1
- 150000003346 selenoethers Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000004763 sulfides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
- 229940098697 zinc laurate Drugs 0.000 description 1
- 229910001656 zinc mineral Inorganic materials 0.000 description 1
- XSMMCTCMFDWXIX-UHFFFAOYSA-N zinc silicate Chemical compound [Zn+2].[O-][Si]([O-])=O XSMMCTCMFDWXIX-UHFFFAOYSA-N 0.000 description 1
- 235000019352 zinc silicate Nutrition 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940006174 zinc valerate Drugs 0.000 description 1
- VRGNUPCISFMPEM-ZVGUSBNCSA-L zinc;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Zn+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O VRGNUPCISFMPEM-ZVGUSBNCSA-L 0.000 description 1
- LPEBYPDZMWMCLZ-CVBJKYQLSA-L zinc;(z)-octadec-9-enoate Chemical compound [Zn+2].CCCCCCCC\C=C/CCCCCCCC([O-])=O.CCCCCCCC\C=C/CCCCCCCC([O-])=O LPEBYPDZMWMCLZ-CVBJKYQLSA-L 0.000 description 1
- WDHVIZKSFZNHJB-UHFFFAOYSA-L zinc;butanoate Chemical compound [Zn+2].CCCC([O-])=O.CCCC([O-])=O WDHVIZKSFZNHJB-UHFFFAOYSA-L 0.000 description 1
- JDLYKQWJXAQNNS-UHFFFAOYSA-L zinc;dibenzoate Chemical compound [Zn+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 JDLYKQWJXAQNNS-UHFFFAOYSA-L 0.000 description 1
- MFMKGXZULQONRI-UHFFFAOYSA-L zinc;diiodate Chemical compound [Zn+2].[O-]I(=O)=O.[O-]I(=O)=O MFMKGXZULQONRI-UHFFFAOYSA-L 0.000 description 1
- GPYYEEJOMCKTPR-UHFFFAOYSA-L zinc;dodecanoate Chemical compound [Zn+2].CCCCCCCCCCCC([O-])=O.CCCCCCCCCCCC([O-])=O GPYYEEJOMCKTPR-UHFFFAOYSA-L 0.000 description 1
- ZPEJZWGMHAKWNL-UHFFFAOYSA-L zinc;oxalate Chemical compound [Zn+2].[O-]C(=O)C([O-])=O ZPEJZWGMHAKWNL-UHFFFAOYSA-L 0.000 description 1
- BUDAIZWUWHWZPQ-UHFFFAOYSA-L zinc;pentanoate Chemical compound [Zn+2].CCCCC([O-])=O.CCCCC([O-])=O BUDAIZWUWHWZPQ-UHFFFAOYSA-L 0.000 description 1
- GQLBMRKEAODAKR-UHFFFAOYSA-L zinc;selenate Chemical compound [Zn+2].[O-][Se]([O-])(=O)=O GQLBMRKEAODAKR-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/30—Copper compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ241653 | 1992-02-19 | ||
| NZ24165392 | 1992-02-19 | ||
| NZ24236192 | 1992-04-14 | ||
| NZ242361 | 1992-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2130443A1 true CA2130443A1 (fr) | 1993-09-02 |
Family
ID=26651052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2130443 Abandoned CA2130443A1 (fr) | 1992-02-19 | 1993-02-17 | Compositions pharmaceutiques et leur utilisation pour le traitement des troubles de carence en zinc |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0626856A1 (fr) |
| AU (1) | AU677179B2 (fr) |
| BR (1) | BR9305932A (fr) |
| CA (1) | CA2130443A1 (fr) |
| HU (1) | HUT69388A (fr) |
| WO (1) | WO1993016708A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT739198E (pt) * | 1994-01-20 | 2004-02-27 | Agres Ltd | Dispositivo para administracao de substancias beneficas a ruminantes |
| CN104495910A (zh) * | 2014-11-28 | 2015-04-08 | 江苏省中国科学院植物研究所 | 一种利用长春花叶提取物制备纳米氧化锌的方法 |
| EP3316702A4 (fr) * | 2015-06-30 | 2018-12-05 | Kemin Industries, Inc. | Traitement d'un stress intestinal, thermique et infectieux, chez l'homme et l'animal par supplémentation avec du zinc et de l'acide butyrique |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU556909B2 (en) * | 1978-09-26 | 1986-11-27 | Itt Industries, Inc. | Subcutaneous implant for an animal |
| JPH0768124B2 (ja) * | 1985-08-27 | 1995-07-26 | グリ−ジンク フア−マシユ−テイカルズ リミテツド | 亜鉛グリセロラ−ト錯体及び医薬的適用のための添加 |
| AT394493B (de) * | 1989-05-11 | 1992-04-10 | Homosan Ag | Pharmazeutisches praeparat zur behandlung von lebererkrankungen |
| GB9001121D0 (en) * | 1990-01-18 | 1990-03-21 | Efamol Holdings | Efa compositions and therapy |
-
1993
- 1993-02-17 CA CA 2130443 patent/CA2130443A1/fr not_active Abandoned
- 1993-02-17 BR BR9305932A patent/BR9305932A/pt not_active Application Discontinuation
- 1993-02-17 EP EP93905657A patent/EP0626856A1/fr not_active Ceased
- 1993-02-17 HU HU9402308A patent/HUT69388A/hu unknown
- 1993-02-17 WO PCT/NZ1993/000005 patent/WO1993016708A1/fr not_active Ceased
- 1993-02-17 AU AU36498/93A patent/AU677179B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU677179B2 (en) | 1997-04-17 |
| BR9305932A (pt) | 1997-08-26 |
| HUT69388A (en) | 1995-09-28 |
| WO1993016708A1 (fr) | 1993-09-02 |
| HU9402308D0 (en) | 1994-10-28 |
| EP0626856A1 (fr) | 1994-12-07 |
| AU3649893A (en) | 1993-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Olson | Selenium toxicity in animals with emphasis on man | |
| Raisbeck | Selenosis | |
| US20250041375A1 (en) | Sugar cane extracts for use in animal feeds | |
| Hartley et al. | Muscular dystrophy in New Zealand livestock | |
| JP2023525883A (ja) | コクシジウム症の治療へのｔｌｒ４モジュレーターの使用 | |
| AU761829B2 (en) | Compositions addressing inflammation and/or degenerative disorders | |
| Waller et al. | Evaluation of copper supplementation to control Haemonchus contortus infections of sheep in Sweden | |
| AU677179B2 (en) | Pharmaceutical compositions and their use for treating zinc deficient disorders | |
| Mutlu et al. | Potential effect dietary supplementation of calcium tetraborate in quails exposed to cadmium: Its impact on productive performance, oxidative stress, cecal microflora, and histopathological changes | |
| EP0093123B1 (fr) | Procede de preparation d'une composition permettant d'ameliorer l'utilisation (digestibilite) du fourrage par les animaux | |
| Lopes et al. | Phytotoxins eliminated by milk: a review | |
| EP0071623B1 (fr) | Procédé pour promouvoir la croissance d'animaux monogastriques, de la volaille et des ruminants | |
| Rydberg et al. | The effectiveness of three different methods of iron administration to young pigs | |
| RU2285399C1 (ru) | Способ повышения мясной продуктивности молодняка свиней на откорме | |
| Ochiogu et al. | Serum luteinising hormone, testosterone and total cholesterol levels, libido and testicular histomorphology of male West African Dwarf goats orally or subcutaneously treated with monosodium L-glutamate. | |
| Whitlock | Feed additives and contaminants as a cause of equine disease | |
| MacPherson | 4.3 Oral Treatment of Trace Element Deficiencies in Ruminant Livestock | |
| Suttle et al. | Micronutrient imbalance | |
| Njida et al. | Anti-nutritional constituents of browse plants in animal nutrition: a review. | |
| NZ249598A (en) | Pharmaceutical compositions and their use in treating zinc deficiency disorders | |
| JP6659355B2 (ja) | 飼養動物用腎機能維持剤、腎機能維持用飼料、及び飼養動物の腎機能維持方法 | |
| Abbott | Clinical aspects of trace element and vitamin nutrition | |
| RU2308188C2 (ru) | Применение корма, обработанного полиферментным препаратом "гимизим", при отравлении животных и кур тяжелыми металлами | |
| West et al. | Hypomagnesaemic tetany in sheep | |
| FI64045B (fi) | Foderblandning innehaollande 7-isopropoxiisoflavon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |